Categories: News

Axonics® to Report Third Quarter 2021 Financial Results on November 4

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

IRVINE, Calif.–(BUSINESS WIRE)–Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report third quarter 2021 financial results after the market closes on Thursday, November 4, 2021.

In conjunction with the release, Axonics will host a conference call at 4:30 p.m. Eastern Time. Interested parties may access the live conference call by dialing 866-687-5771 (U.S.) or 409-217-8725 (international) and using passcode 8798817.

A live webcast of the conference call may be accessed by visiting the Events & Presentations section of the Axonics investor relations website. A replay of the webcast will be available shortly after the conclusion of the conference call and will be archived on the Axonics website.

About Axonics

Based in Irvine, Calif., Axonics is a global medical technology company that is developing and commercializing novel products for patients with bladder and bowel dysfunction. The company’s rechargeable sacral neuromodulation (SNM) system provides patients suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, Axonics’ best-in-class urethral bulking agent, Bulkamid®, provides women suffering from stress urinary incontinence (SUI) with safe and durable symptom relief.

Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults estimated to suffer from fecal incontinence. SUI affects an estimated 20 million women in the U.S. alone. Axonics’ clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. For more information, visit www.axonics.com.

Contacts

Neil Bhalodkar

Investor Relations

949-336-5293

ir@axonics.com

Staff

Recent Posts

St. Baldrick’s Foundation Launches June Campaign to Honor Childhood Cancer Survivors and Support Lifesaving Research

Los Angeles, California--(Newsfile Corp. - June 3, 2025) - This National Cancer Survivor Month, St.…

3 hours ago

ThinkCyte Unveils MorphoScan Cloud: A Versatile Cloud-Based Platform for AI-Driven Cell Morphology Data Analysis

TOKYO, June 3, 2025 /PRNewswire/ -- ThinkCyte, a life science company pioneering advanced AI-powered cell…

3 hours ago

Healthie Launches Dev Assist: AI-Native Tooling for Rapid Healthcare App Development, Powered by the Model Context Protocol (MCP)

New open-source tool connects Healthie's GraphQL API to leading AI assistants via the Model Context…

3 hours ago

MATTERWORKS INC. SECURES SERIES A FUNDING TO ADVANCE MACHINE INTELLIGENCE FOR PREDICTIVE BIOLOGY

SOMERVILLE, Mass., June 3, 2025 /PRNewswire/ -- Matterworks, Inc., the category-defining pioneer unlocking unstructured molecular…

3 hours ago

Digital Pathology Market worth US$2.75 billion by 2030 with 13.5% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., June 3, 2025 /PRNewswire/ -- The global Digital Pathology Market, valued at US$1.29…

3 hours ago

Seven Corners Healthcare Invests in MobileOp4, Advancing Medical Access in Disasters and Rural Communities

CARMEL, Ind., June 3, 2025 /PRNewswire/ -- In further commitment to increasing health care access…

3 hours ago